MoneyGram International, Inc. ( MGI Quick Quote MGI - Free Report) has partnered with Sigue Corporation, a leading U.S.-based transnational P2P and B2B payment company.
Per the agreement, MoneyGram will allow Sigue to use its domestic and international receive network.
With this deal, Sigue will be able to plug into MoneyGram’s modern mobile and API-driven global network to be able to provide their customers with expanded services.
By aiding Sigue customers to use its global network, MoneyGram will benefit from expanded payment volumes made via network and process additive transactions. MoneyGram built a vast tech-enabled and scalable global payments infrastructure that can absorb significant volume at a very marginal cost.
Thus, the deal is win-win for both parties involved. While Sigue will gain from accessing a high tech global money transfer network without making any investment in infrastructure, MoneyGram will benefit from increased processing revenues from Sigue’s payments routed via its network.
This deal falls under MoneyGram’s new business line named ‘MoneyGram as a Service ,' which enables other companies to avail of its leading global money transfer network through its powerful API-driven infrastructure and best-in-class technology. This new business line, which was launched late last month, represents a significant growth opportunity for MoneyGram as it enters a market estimated to be $17 billion in 2024, seeing a CAGR of about 24% over the forecast period .
With MoneyGram as a Service, enterprise customers will be able to use the company’s core capabilities as productized service offerings to meet their various business needs and quickly add services and scale. A productized service offering is a specially ‘done for you’ solution.
MoneyGram as a Service already partnered with Emergent Technology Ltd., which is the owner and operator of the G-Coin digital token. MoneyGram will facilitate fast and easy cash funding and payout of the purchase and sale of digital gold via its powerful API-driven infrastructure and best-in-class technology.
Following the COVID-19 outbreak, the company’s digital transactions gained an added impetus as more customers opted for digital channels to make their payments. This was clearly evident in the fourth quarter of 2020, which reflected the successful digital transformation journey of MoneyGram.
A robust digital arm bodes well for MoneyGram as its revenues have been declining since 2017 through 2020. Revenues are also persistently affected by a higher compliance-control strategy and stiff competition.
The company began laying the groundwork for its digital transformation four years ago to embrace the rapid changes brought about with the expansion of technology in the remittance industry. Its consumer direct channel MGO is the largest component of its overall digital business and a steady catalyst for customer acquisitions.
Via its digital business, the company is exploring new geographies and continuously wooing a completely new customer base.
With several fintech players, such as
PayPal Holdings, Inc. ( PYPL Quick Quote PYPL - Free Report) , Square, Inc. ( SQ Quick Quote SQ - Free Report) and others offering similar services at affordable rates, competition for MoneyGram naturally intensified over the years. Its close peer Western Union Co. ( WU Quick Quote WU - Free Report) is also facing the same rivalry and is constantly pursuing technological investments to stay ahead in the race.
Year to date, the stock has risen 25.3% compared with its
industry’s growth of 8.7%.
MoneyGram carries a Zacks Rank #4 (Sell) at present.
You can see
. the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>